Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 949 participants.
Also called NCT01425359
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 949 participants
- Sponsor
- Registry
-
NCT01425359
-
- Other papers using this trial's data
- Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial
- Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belarus, Bulgaria, Canada, Czechia, Georgia, Germany, Israel, Poland, Russia, Serbia, Slovakia, Slovenia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01425359. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
- Acronym
- TERISA
- Condition
- Angina Pectoris
- Condition
- Coronary Artery Disease
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Ranolazine placebo
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct01425359- Content hash
cc9d2c90420a15ea2439a81f64f0ca5d2d3a69af459d4ab1827c0e6580b5a971